Telomir Pharmaceuticals (TELO) Projected to Post Quarterly Earnings on Monday

Telomir Pharmaceuticals (NASDAQ:TELO) is expected to be issuing its quarterly earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Telomir Pharmaceuticals (NASDAQ:TELO) last issued its earnings results on Tuesday, February 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). On average, analysts expect Telomir Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Telomir Pharmaceuticals Trading Down 1.2 %

Shares of TELO stock opened at $2.49 on Friday. The firm has a market capitalization of $74.11 million, a price-to-earnings ratio of -4.29 and a beta of 0.17. The business’s 50-day moving average price is $3.26 and its 200-day moving average price is $4.08. Telomir Pharmaceuticals has a 12 month low of $2.35 and a 12 month high of $8.40.

Analyst Upgrades and Downgrades

TELO has been the topic of a number of research reports. Rodman & Renshaw initiated coverage on shares of Telomir Pharmaceuticals in a report on Friday, February 21st. They set a “buy” rating and a $15.00 target price on the stock. RODMAN&RENSHAW raised shares of Telomir Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, February 20th.

Hedge Funds Weigh In On Telomir Pharmaceuticals

An institutional investor recently raised its position in Telomir Pharmaceuticals stock. Bank of America Corp DE raised its position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) by 283.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 14,713 shares of the company’s stock after purchasing an additional 10,880 shares during the period. Bank of America Corp DE’s holdings in Telomir Pharmaceuticals were worth $61,000 as of its most recent filing with the SEC.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.